SCHEMBL1009679

SCHEMBL1009679

C=CCN1CCC(c2cc(F)cc(S(C)(=O)=O)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.46
SIGMAR1 Q99720 1/20 0.46
DRD3 P35462 1/20 0.36
NPY5R Q15761 2/20 0.35
HCRTR2 O43614 3/20 0.34
CCR5 P51681 2/20 0.33
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
PTGS2 P35354 1/20 0.33
DRD4 P21917 1/20 0.33
CCR2 P41597 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Seridopidine SCHEMBL29941400 0.84 DRD2 (0.53) DRD2SIGMAR1DRD3NPY5RHCRTR2
Seridopidine SCHEMBL1008691 0.84 DRD2 (0.53) DRD2SIGMAR1DRD3NPY5RHCRTR2
Seridopidine SCHEMBL1010113 0.83 DRD2 (0.52) DRD2SIGMAR1DRD3NPY5RHCRTR2
SCHEMBL4825019 0.82 DRD2 (0.69) DRD2SIGMAR1DRD3NR1H2NR1H3
SCHEMBL1009377 0.82 DRD2 (0.68) DRD2SIGMAR1DRD3
Hydrochloric Acid SCHEMBL1010782 0.81 DRD2 (0.67) DRD2SIGMAR1DRD3
SCHEMBL1011686 0.72 HTR6 (0.41) SIGMAR1HCRTR2PTGS2
SCHEMBL2781495 0.70 SIGMAR1 (0.39) DRD2SIGMAR1DRD3HCRTR2DRD4
SCHEMBL82136 0.67 SLC18A3 (0.45) DRD2DRD3DRD4
SCHEMBL175904 0.67 SLC18A3 (0.57) DRD2SIGMAR1CCR5DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1948606-B1 3, 5-DISUBSTITUTED PHENYL-PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB AF NEUROSEARCH SWEDEN AB (DK) 2011-01-05 EP claimed
US-20080234321-A1 3,5-Disubstituted Phenyl-Piperidines as Modulators of Dopamine Neurotransmission SANIONA AB (DK) 2008-09-25 US claimed
US-8501777-B2 1-ethyl-4-[3-fluoro-5-(methylsulfonyl)phenyl]piperidine; central nervous system disorders, Parkinson's disease, Parkinsonism, dyskinesias, including L-DOPA induced dyskinesias, dystonias, tics, tremor, Huntington disease NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2013-08-06 US disclosed
EP-1948606-B1 3, 5-DISUBSTITUTED PHENYL-PIPERIDINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION NSAB AF NEUROSEARCH SWEDEN AB (DK) 2011-01-05 EP disclosed
US-20080234321-A1 3,5-Disubstituted Phenyl-Piperidines as Modulators of Dopamine Neurotransmission SANIONA AB (DK) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234321-A1 3,5-Disubstituted Phenyl-Piperidines as Modulators of Dopamine Neurotransmission SLC6A3, DRD2, DRD3 DRD2 2/4885SIGMAR1 148/4885DRD3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.